Option chain shows key data for Lexaria Bioscience's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Lexaria Bioscience.

Lexaria Bioscience (NASDAQ:LEXXW) Stock, Option Chain

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

Biotech

News

Penny Stocks

Health Care

Movers

General

LEXX

LEXXW

Lexaria&#39;s Formulated Cannabidiol Showed Reduction In Pro-Inflammatory Biomarkers Associated with Heart Diseases

Cannabis

Markets

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) (NASDAQ: LEXXW) diabetes animal model study DIAB-A22-1 has been completed and produced at least three positive outcomes including weight loss in 

Lexaria&#39;s DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride And Cholesterol Levels

Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) revealed that dosing with Lexaria&#39;s DehydraTECH-processed CBD has been completed in its multi-week human clinical hypertension study HYPER-H21-4

Lexaria&#39;s DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Events

Lexaria Bioscience Corp

Press Releases

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Lexaria Releases Annual Letter from the CEO

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Lexaria Bioscience

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Lexaria Bioscience

Lexaria Bioscience (LEXXW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga